Spruce Biosciences
SPRB
32 hedge funds and large institutions have $48.3M invested in Spruce Biosciences in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
16.51% less ownership
Funds ownership: 70.43% → 53.92% (-17%)
26% less capital invested
Capital invested by funds: $65.6M → $48.3M (-$17.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.72M |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$690K |
| 3 |
SC
Stempoint Capital
New York
|
+$439K |
| 4 |
Goldman Sachs
New York
|
+$380K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$3.99M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.16M |
| 3 |
CP
Caligan Partners
New York
|
-$1.79M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.72M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$1.06M |
SPRB Hedge Fund Activity: Q1 2026 in Review
32 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2026, worth a combined $48.3M — down 26% from $65.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SPRB positions and 9 closed out — a net gain of 1 holder — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $7.72M. The largest seller was Squadron Capital Management, cutting an estimated $3.99M.
- 32 institutional investors held Spruce Biosciences (SPRB) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $48.3M of Spruce Biosciences stock for Q1 2026, down 26% quarter-over-quarter.
- 10 funds opened new Spruce Biosciences positions in Q1 2026 and 9 closed out, a net change of +1 holder.
- The largest Spruce Biosciences buyer in Q1 2026 was Millennium Management, an estimated $7.72M added.
- The largest Spruce Biosciences seller in Q1 2026 was Squadron Capital Management, an estimated $3.99M sold.
Based on aggregated 13F filings for Q1 2026.